These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 37469973)
1. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J Front Immunol; 2021; 12():669750. PubMed ID: 34054840 [TBL] [Abstract][Full Text] [Related]
3. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy. Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640 [TBL] [Abstract][Full Text] [Related]
4. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer. Liu X; Ma C; Liu H; Sun Z; Luo J J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010 [TBL] [Abstract][Full Text] [Related]
5. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment. Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566 [TBL] [Abstract][Full Text] [Related]
6. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy. Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma. Yu ZL; Zhu ZM Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330 [TBL] [Abstract][Full Text] [Related]
8. The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma. Qin S; Liu G; Jin H; Chen X; He J; Xiao J; Qin Y; Mao Y; Zhao L Aging (Albany NY); 2022 Aug; 14(15):6269-6298. PubMed ID: 35963644 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X Front Immunol; 2022; 13():976107. PubMed ID: 36091006 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma. Yin T; Zhao L; Yao S BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168 [TBL] [Abstract][Full Text] [Related]
11. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma. Huang X; Qiu Z; Li L; Chen B; Huang P Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607 [TBL] [Abstract][Full Text] [Related]
12. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Jiang H; Ning G; Wang Y; Lv W Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302 [TBL] [Abstract][Full Text] [Related]
14. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992 [TBL] [Abstract][Full Text] [Related]
15. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. Kong F; Wang K; Wang L Discov Oncol; 2022 Nov; 13(1):131. PubMed ID: 36434140 [TBL] [Abstract][Full Text] [Related]
18. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model. Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737 [TBL] [Abstract][Full Text] [Related]
19. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance. Zhao H; Zhou Q; Shi C; Shao Y; Ni J; Lou J; Wei S Med Sci Monit; 2021 Oct; 27():e930994. PubMed ID: 34690344 [TBL] [Abstract][Full Text] [Related]
20. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]